NCT03350191 - A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

June 7, 2018

Study Completion Date

June 7, 2018

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

SAR425899

"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"

DRUG

[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)

"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"

DRUG

[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)

"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"

Trial Locations (1)

Investigational Site Number 7520001, Uppsala